Key result
Aspirin plus low-dose rivaroxaban reduces cardiovascular events in chronic coronary disease but increases major bleeding.
Why the study?
Whether aspirin plus low-dose rivaroxaban versus aspirin alone reduces cardiovascular events without excess major bleeding in adults with chronic coronary disease was examined.
Does aspirin plus low-dose rivaroxaban reduce cardiovascular events without excess major bleeding in adults with chronic coronary disease?
Does aspirin plus low-dose rivaroxaban reduce cardiovascular events without excess major bleeding in adults with chronic coronary disease?
In adults with chronic coronary disease, adding low-dose rivaroxaban to aspirin reduces cardiovascular events but increases major bleeding, requiring individualized risk-benefit assessment.
Answers are grounded in this paper and cite their sources.
Patient-specific risk-benefit assessment warranted in chronic coronary disease; leaves open optimal subgroup selection for combination therapy.
Evidence shows that in adults with chronic coronary disease, aspirin plus low-dose rivaroxaban reduces cardiovascular events compared to aspirin alone, but at the cost of increased major bleeding. This necessitates patient-specific consideration of risks and benefits.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question. Aspirin plus low-dose rivaroxaban reduces cardiovascular events compared to aspirin alone in adults with chronic coronary disease, but increases the risk of major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: